The MED-C N1 Registry is a major advancement in cancer research. This important patient-centric initiative brings together insurance companies, precision medicine laboratories, providers and pharmaceutical companies to help advance diagnosis and treatment of cancer. Although starting in lung cancer, the registry will eventually encompass all tumor types. MED-C, is a 501(c)(3) non-profit organization that operates as an independent, honest and unifying body who has no other purpose then to help advance personalized medicine. The data that is collected by this initiative will be widely available for research by all groups, who working together, can achieve new milestones in cancer treatment. The N1 Registry is enrolling in four distinct steps:
Step 1 – Insurance coverage of testing as part of registry
Step 2 – Enrolling laboratories that meet the high quality standard and that have been approved by MED-C
Step 3 – Enrolling clinics as sites in the registry
Step 4 – Enrolling patients into the registry
STATUS UPDATE: MED-C is working with several insurance providers to become an approved quality patient registry. When a payor agrees to participate, MED-C will begin to identify and approve quality next generation sequencing labs. Once a laboratory has been accepted, clinics can begin enrolling into the N1 Registry, become IRB approved, and can begin to enroll their lung cancer patients.